Report of Foreign Issuer (6-k)
March 14 2017 - 1:28PM
Edgar (US Regulatory)
United
States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the Month of March, 2017
Commission File Number: 001-35892
GW
PHARMACEUTICALS PLC
(Translation of registrant’s name
into English)
Sovereign
House
Vision
Park
Histon
Cambridge
CB24 9BZ
United
Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Results of Annual Meeting of Shareholders
On March 14, 2017, GW Pharmaceuticals plc (the “Company”)
announced that it held its annual general shareholder meeting that day and that all the resolutions set out in the notice of meeting
sent to shareholders were duly proposed and passed. A summary of the results of the meeting is attached hereto as Exhibits 99.1
and is incorporated by reference herein. On March 14, 2017, the Company also updated its corporate presentation. A copy of the
updated corporate presentation is attached hereto as Exhibit 99.2 and is incorporated by reference herein.
The information contained in Exhibit 99.1 and Exhibit 99.2 shall
not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless
expressly set forth by specific reference in such a filing.
Exhibits
|
99.1
|
Announcement of Results of Annual General Meeting
|
|
99.2
|
Updated Corporate Presentation dated March 2017
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
GW Pharmaceuticals plc
|
|
|
|
|
By:
|
/s/ Adam George
|
|
Name:
|
Adam George
|
|
Title:
|
Company Secretary
|
|
|
|
Date: March 14, 2017
|
|
|